azacitidine has been researched along with Recrudescence in 129 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.33) | 18.7374 |
| 1990's | 6 (4.65) | 18.2507 |
| 2000's | 10 (7.75) | 29.6817 |
| 2010's | 77 (59.69) | 24.3611 |
| 2020's | 33 (25.58) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, F; Beguin, Y; Berneman, Z; De Becker, A; Deeren, D; Graux, C; Herman, J; Kerre, T; Lewalle, P; Ory, A; Poiré, X; Schoemans, H; Selleslag, D; Zachée, P | 1 |
| Beach, CL; Döhner, H; Dombret, H; La Torre, I; Menezes, DL; Ossenkoppele, G; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Schuh, AC; Skikne, B; Thol, F; Voso, MT; Wei, AH; Zhong, J | 1 |
| Bewersdorf, JP; Gowda, L; Prebet, T | 1 |
| Gafter-Gvili, A; Gurion, R; Raanani, P; Sherban, A; Wolach, O | 1 |
| Tang, Y; Yan, H; You, Y; Zhou, Z | 1 |
| Dai, H; Gao, X; Li, Y; Wang, W; Xue, Y; Yao, D | 1 |
| Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I | 1 |
| Boyadzhiev, H; Ganster, C; Haase, D; Hasenkamp, J; Jung, W; Koch, R; Maulhardt, M; Mazzeo, P; Schmidt, N; Shumilov, E; Wulf, G | 1 |
| Bertani, G; Calado, RT; Daigle, SR; de Botton, S; Döhner, H; Gianolio, DA; Heuser, M; Hui, J; Montesinos, P; Pandya, SS; Recher, C; Schuh, AC; Vives, S; Wang, J; Yeh, SP; Zarzycka, E | 1 |
| Giubellino, A; Nasrollahi, E; Rashidi, A | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Berthon, C; Carpentier, B; Chauvet, P; Goursaud, L; Lionne-Huyghe, P; Nibourel, O; Quesnel, B; Wemeau, M | 1 |
| Abou Dalle, I; Bazarbachi, A; Brissot, E; El-Cheikh, J; Kreidieh, F; Mohty, M; Moukalled, N | 1 |
| Abbott, D; Bosma, G; Gutman, JA; Jordan, C; Minhajuddin, M; Pollyea, DA; Winters, AC | 1 |
| Beach, CL; Chan, ET; Döhner, H; Dombret, H; Lopes de Menezes, D; Montesinos, P; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Sandhu, I; See, WL; Skikne, B; Thakurta, A; Thol, FR; Ugidos, M; Wei, AH | 1 |
| Holter-Chakrabarty, J; Keruakous, AR; Khawandanah, MO; Schmidt, SA; Selby, G; Yuen, C | 1 |
| Bourke, C; Cummings, NJ; Curtis, DJ; Das, TP; Fleming, SA; Ivey, A; Kliman, DS; North, D; O'Brien, ME; Patil, SS; Spencer, A; Swain, MI; Tan, JLC; Widjaja, JML | 1 |
| Abe, H; Hamada, S; Hyakuna, N; Nakanishi, K; Oshiro, T | 1 |
| Najima, Y | 1 |
| Cao, Y; Chen, X; Feng, S; Guo, W; Han, M; He, Y; Jiang, E; Liu, J; Liu, X; Ma, Q; Pang, A; Wang, M; Wei, J; Yang, D; Zhai, W; Zhang, R; Zheng, Y | 1 |
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Alvarado, Y; Bhalla, KN; Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Fiskus, WC; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, T; Khoury, JD; Konopleva, M; Masarova, L; Miller, D; Pemmaraju, N; Pierce, S; Qiao, W; Ravandi, F; Sasaki, K; Senapati, J; Short, NJ; Wilson, NR | 1 |
| Li, Q; Liu, K; Yang, S; Zeng, Q; Zheng, F; Zhou, Z | 1 |
| Fan, C; Jiang, H; Jin, J; Li, J; Lou, Y; Lu, Y; Ma, Y; Mao, L; Shao, L | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Hiroshima, Y; Kazumoto, H; Kirihara, T; Kitahara, M; Kobayashi, H; Sato, K; Shishido, T; Sumi, M; Ueki, T; Uematsu, N | 1 |
| DiNardo, CD; Döhner, H; Esteve, J; Fenaux, P; Garcia, JS; Hájek, R; Havelange, V; Hong, WJ; Illés, Á; Jang, JH; Jonas, BA; Koller, E; Konopleva, M; Lavie, D; Leber, B; Lemoli, RM; Letai, A; Pejsa, V; Porkka, K; Potluri, J; Pratz, KW; Pullarkat, V; Thirman, MJ; Turgut, M; Wang, J; Wei, AH; Yamamoto, K; Yeh, SP; Yoon, SS; Zhou, Y | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| Bai, L; Liu, SB; Ma, X; Qian, CS; Sun, AN; Wang, J; Wang, TJ; Wu, DP; Xu, MZ; Xue, SL; Zhou, HX | 1 |
| DiNardo, CD | 1 |
| Bourgeois, AL; Bris, YL; Ceballos, P; Chevallier, P; François, S; Fronteau, C; Garnier, A; Giltat, A; Guillaume, T; Orvain, C; Peterlin, P; Planche, L; Thépot, S | 1 |
| Beelen, D; Bethge, W; Bleckert, G; Buchner, H; Bug, G; Giagounidis, A; Haase, D; Heinzelmann, M; Kobbe, G; Kröger, N; Krönke, J; Nolte, F; Platzbecker, U; Schäfer-Eckart, K; Scheid, C; Schlenk, RF; Sockel, K; Stadler, M; Stelljes, M; Wolf, D; Wolschke, C; Wulf, G | 1 |
| Dezern, AE; Gojo, I; Jones, RJ; Morrow, J; Prince, GT; Showel, M; Smith, BD; Symons, H; Webster, JA; Yogarajah, M; Zahurak, M | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bazarbachi, A; Charafeddine, M; El-Cheikh, J; Fares, E; Kharfan-Dabaja, MA; Kreidieh, N; Mahfouz, R; Massoud, R | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Baker, K; Deeg, HJ; Festuccia, M; Gooley, TA; Sandmaier, BM; Scott, BL | 1 |
| Chijimatsu, I; Eguchi, M; Fujita, N; Hamamoto, K; Imanaka, Y; Karakawa, S; Miki, M; Nishimura, S; Tomizawa, D | 1 |
| Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T | 1 |
| Bornhäuser, M; Bug, G; Germing, U; Geyh, S; Haas, R; Hopfer, O; Klein, S; Kobbe, G; Kondakci, M; Krüger, W; Nachtkamp, K; Platzbecker, U; Rautenberg, C; Schroeder, T; Steinmann, J | 1 |
| Burkett, S; Cam, MC; Cunningham, T; Jailwala, P; Müller, F; Pastan, I; Stetler Stevenson, M; Stookey, S; Tai, CH; Wayne, AS | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Baldus, CD; Bochtler, T; Borkmann, C; Bornhäuser, M; Bug, G; Dührsen, U; Ehninger, G; Fransecky, L; Götze, KS; Groth, C; Hänel, M; Herbst, R; Krämer, A; Kramer, M; Kubasch, AS; Mende, M; Middeke, JM; Mütherig, A; Noppeney, R; Oelschlägel, U; Platzbecker, U; Röllig, C; Schetelig, J; Schubert, A; Serve, H; Sockel, K; Stelljes, M; Stölzel, F; Thiede, C; von Bonin, M; Wolf, D | 1 |
| Brock, K; Cavenagh, J; Craddock, C; De Santo, C; Dennis, M; Ferguson, P; Hodgkinson, A; Ingram, W; Malladi, R; Mussai, F; Siddique, S; Slade, D; Wheat, R; Yap, C | 1 |
| Bewersdorf, JP; Stahl, M; Zeidan, AM | 1 |
| Benayoun, E; Cordonnier, C; Maury, S; Pautas, C; Rahmé, R; Wagner-Ballon, O | 1 |
| Bug, G; Cadeddu, RP; Czibere, A; Dienst, A; Fenk, R; Fröbel, J; Germing, U; Haas, R; Kobbe, G; Kröger, N; Platzbecker, U; Schroeder, T; Uharek, L | 1 |
| Chantepie, SP; Charbonnier, A; Gruson, B; Harrivel, V; Ivanoff, S; Lemasle, E; Marolleau, JP; Merlusca, L; Royer, B; Votte, P | 1 |
| Abhyankar, S; Aljitawi, O; Bhalla, KN; Dutreix, C; Fiskus, W; Fleming, A; Ganguly, S; Kambhampati, S; McGuirk, JP; Reyes, R; Wick, J; Williams, CB | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Bechelli, J; Becker, MW; Chen, R; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Minhajuddin, M; Mulford, D; O'Dwyer, K; Phillips, GL; Rosell, K; Walker, A | 1 |
| Estey, EH; Gallegos, L; Gardner, KM; Hendrie, PC; Medeiros, BC; Orlowski, KF; Scott, BL; Walter, RB | 1 |
| Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM | 1 |
| Chizuka, A; Kojima, R; Miyakoshi, S; Miyamoto, K; Ogasawara, T; Ueda, S | 1 |
| Abboud, CN; Cashen, AF; Dipersio, JF; Jacoby, M; Niu, H; Pusic, I; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A | 1 |
| Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
| Schlenk, RF; Thol, F | 1 |
| Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H | 1 |
| Bacigalupo, A; Bregante, S; Colombo, N; Di Grazia, C; Dominietto, A; Galaverna, F; Geroldi, S; Ghiso, A; Grasso, R; Gualandi, F; Lamparelli, T; Luchetti, S; Raiola, AM; Stasia, A; Van Lint, MT; Varaldo, R | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Adès, L; Berthon, C; Bouscary, D; Caillot, D; Cluzeau, T; Dartigeas, C; Delaunay, J; Devidas, A; Dombret, H; Fenaux, P; Gardin, C; Guièze, R; Ifrah, N; Itzykson, R; Marolleau, JP; Plantier, I; Prébet, T; Recher, C; Stamatoullas, A; Taksin, AL; Thépot, S; Turlure, P; Vey, N | 1 |
| Beelen, DW; Bornhäuser, M; Bug, G; Czibere, A; Dienst, A; Fenk, R; Germing, U; Haas, R; Klein, S; Kobbe, G; Kondakci, M; Kröger, N; Luft, T; Nachtkamp, K; Platzbecker, U; Rachlis, E; Ringhoffer, M; Schroeder, T; Stadler, M; Steckel, NK; Stelljes, M; Uharek, L; Wolf, D | 1 |
| Alholle, A; Bauer, J; Brini, AT; Gentle, D; Gharanei, S; Grimer, R; Jeys, L; Latif, F; Maher, ER; Niada, S; Slater, A; Sumathi, VP | 1 |
| Brandwein, J; Brian, L; Chen, EX; Degelder, T; Egorin, MJ; Espinoza-Delgado, I; Gupta, V; Haines, P; Holleran, JL; How, J; McGill, S; Minden, MD; Piekarz, R; Schimmer, AD; Schuh, AC; Siu, LL; Stayner, LA; Wang, L; Webster, S; Wong, T; Yee, KW | 1 |
| Dunleavy, K; Jiang, Z; Kuo, PY; Leshchenko, VV; Overbey, J; Parekh, S; Weniger, MA; Wiestner, A; Wilson, WH | 1 |
| Doki, N; Ikegawa, S; Kakihana, K; Kobayashil, T; Ohashi, K; Oshikawa, G; Sakamaki, H; Shingai, N; Takahashi, Y; Yoshioka, K | 1 |
| Chim, CS; Li, ZY; Wang, LQ; Wong, KY; Zhang, Q | 1 |
| Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y | 1 |
| Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J | 1 |
| Bai, F; Cheerva, AC; Diller, L; George, RE; Krishnadas, DK; Lucas, KG; Shusterman, S; Sullivan, JE | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Buka, R; Byrne, J; Craddock, C; Crawley, C; Dennis, M; Ferguson, P; Goodyear, O; Hazlewood, P; Jilani, N; Khan, J; Malladi, R; Nagra, S; Russell, N; Siddique, S; Snowden, J; Tholouli, E; Vyas, P; Ward, J; Yap, C | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Deng, M; Li, R; Li, Z; Xiao, X; Yang, J; Zhang, G | 1 |
| Blaise, D; Bourhis, JH; Chevallier, P; Craddock, C; Finke, J; Hallek, M; Kröger, N; Labopin, M; Luft, T; Mohty, M; Nagler, A; Robin, M; Sengelov, H; Yakoub-Agha, I | 1 |
| Abboud, C; Cashen, A; Choi, J; DiPersio, J; Eissenberg, LG; Fiala, MA; Fletcher, T; Ghobadi, A; Jacoby, M; Liu, J; Pusic, I; Schroeder, MA; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Liu, H; Sun, Z; Tang, B; Tong, J; Zhang, L; Zhang, X; Zheng, C; Zhou, H; Zhu, X | 1 |
| Deeg, HJ; Fang, M; Mielcarek, M; Scott, BL; Storer, B; Woo, J; Yeung, C | 1 |
| Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhao, YS | 1 |
| Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N | 1 |
| Artz, A; Churpek, JE; Godley, LA; Hantel, A; Khan, N; King, D; Knoebel, RW; Larson, RA; Liu, H; Odenike, O; Stock, W; Thirman, MJ | 1 |
| DeRemer, DL; Farrow, S; Jillella, A; Kalla, A; Ustun, C | 1 |
| Champlin, R; de Lima, M; de Padua, L; Garcia-Manero, G; Giralt, S; Jabbour, E; Jagasia, M; Kantarjian, H; Kebriaei, P; Shpall, EJ | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Thiede, C; Wermke, M | 1 |
| Bruns, I; Czibere, A; Fenk, R; Germing, U; Gräf, T; Haas, R; Kobbe, G; Kröger, N; Lind, J; Platzbecker, U; Schröder, T; Zohren, F | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, MS; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Anders, V; Bolaños-Meade, J; Villela, L | 1 |
| Brown, R; Cogle, CR; Hsu, J; Imanirad, I; Scornik, JC; Wiggins, LE; Wingard, JR | 1 |
| Braun, TM; Champlin, R; de Lima, M; de Padua Silva, L; Garcia-Manero, G; Giralt, S; Jones, RB; Komanduri, K; Nguyen, HQ; Thall, PF | 1 |
| Halasz, C; Patel, V; Ruskin, A; Tintle, S | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Radke, J; Schaich, M; Sockel, K; Thiede, C; Wermke, M | 1 |
| Bornhäuser, M; Ehninger, G; Graehlert, X; Kiani, A; Klut, IM; Knoth, H; Mohr, B; Oelschlaegel, U; Platzbecker, U; Radke, J; Röllig, C; Schetelig, J; Seltmann, F; Thiede, C; Wermke, M | 1 |
| Bollard, CM; Copeland, A; Cruz, CR; Gerdemann, U; Heslop, HE; Horton, TM; Ku, S; Leen, AM; Rooney, CM; Shafer, JA; Sheehan, A; Tzou, B; Younes, A | 1 |
| Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB; Zhang, H; Zhu, ZA | 1 |
| Chim, CS; Jin, DY; Liang, R; So, CC; Wong, KY; Yim, RL | 1 |
| Akpek, G; Cao, Q; Gojo, I; Rapoport, AP; Singh, SN | 1 |
| Appelbaum, FR; Deeg, HJ; Estey, EH; Gerds, AT; Gooley, TA; Scott, BL | 1 |
| Brooks, J; Jarrard, DF; Kobayashi, Y; Rajamanickam, V; Truong, M; Wagner, J; Yang, B | 1 |
| Barreyro, L; Ben-Neriah, S; Bhagat, TD; Bhattacharyya, S; Boultwood, J; Greally, JM; Heuck, C; List, AF; Maciejewski, J; McMahon, C; Mo, Y; Montagna, C; Parekh, S; Pellagatti, A; Schinke, C; Silverman, L; Steidl, C; Steidl, U; Tamari, R; Verma, A; Vogler, TO; Will, B; Ye, BH; Yu, Y; Zhou, L | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Abhyankar, S; Aljitawi, OS; Amin, M; Divine, C; Ganguly, S; McGuirk, JP | 1 |
| Krishnadas, DK; Lucas, K; Shapiro, T | 1 |
| Carlson, K; Christos, PJ; Feldman, EJ; Ippoliti, C; Lagassa, CB; Ritchie, EK; Roboz, GJ; Rohan, SD; Scandura, JM | 1 |
| Antar, A; Aractingi, S; Bazarbachi, A; Kharfan-Dabaja, M; Mohty, M; Otrock, ZK; Salem, Z | 1 |
| Mitrovic, M; Pleyer, L; Stauder, R; Steurer, M; Valentiny, C; Willenbacher, W | 1 |
| Ishigatsubo, Y; Kanamori, H; Maruta, A; Matsumoto, K; Ogusa, E; Tachibana, T; Yamamoto, W | 1 |
| Bruns, I; Bug, G; Czibere, A; Fenk, R; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kröger, N; Luft, T; Platzbecker, U; Rieger, K; Schroeder, T; Uharek, L; Wolschke, C; Zohren, F | 1 |
| Alimena, G; Bari, A; Breccia, M; Fianchi, L; Finelli, C; Leone, G; Lunghi, M; Musto, P; Niscola, P; Poloni, A; Voso, MT; Zambello, R | 1 |
| Emi, N; Iwai, M; Kinoshita, T; Kiyoi, H; Naoe, T; Ohno, R; Ozeki, K | 1 |
| Chan, WW; Chim, CS; Kwong, YL; Pang, A | 1 |
| Lübbert, M; Rüter, B; Wijermans, PW | 1 |
| Fenk, R; Graef, T; Haas, R; Kobbe, G; Kuendgen, A; Zohren, F | 1 |
| Cashen, AF; Devine, H; DiPersio, J | 1 |
| Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Cabanillas, F | 1 |
| Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Archimbaud, E; Muus, P; Willemze, R | 1 |
| Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R | 1 |
| Jakubowski, A; Kritz, AD; Maslak, P; Menendez-Botet, C; Raptis, G | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Champlin, R; Davis, M; de Vos, D; Giralt, S; Kantarjian, H; O'Brien, S; van Besien, K | 1 |
| Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Cohen, A; Davis, M; deVos, D; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Korbling, M; O'Brien, S; Ravandi, F; Ueno, N | 1 |
| Colly, LP; Kluin-Nelemans, JC; Richel, DJ; Willemze, R | 1 |
11 review(s) available for azacitidine and Recrudescence
| Article | Year |
|---|---|
Azacitidine maintenance in AML post induction and posttransplant.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction | 2022 |
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Topics: Acute Disease; Azacitidine; Decitabine; Disease-Free Survival; Enzyme Inhibitors; Humans; Leukemia, Myeloid; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Transplantation, Homologous | 2022 |
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
Topics: Azacitidine; Chronic Disease; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Transplantation, Homologous | 2023 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
Topics: Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Recurrence; Transplantation, Homologous | 2021 |
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Topics: Allografts; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Secondary Prevention; Stem Cell Transplantation | 2018 |
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Gemtuzumab; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure | 2014 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
35 trial(s) available for azacitidine and Recrudescence
| Article | Year |
|---|---|
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Topics: Antimetabolites; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction | 2022 |
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukopenia; Pyridines; Recurrence | 2022 |
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Topics: Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction | 2022 |
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Pneumonia; Recurrence; Remission Induction; Sulfonamides; Thrombocytopenia | 2020 |
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous | 2021 |
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic synd
Topics: Azacitidine; Bone Marrow; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence | 2021 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Nucleophosmin; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors | 2018 |
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Failure; United Kingdom; Young Adult | 2019 |
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cohort Studies; Decitabine; Drug Synergism; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Recurrence; Staurosporine | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Recurrence; Sirolimus | 2013 |
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Vorinostat | 2014 |
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2014 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2014 |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperglycemia; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vincristine; Young Adult | 2014 |
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate | 2015 |
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Vorinostat | 2015 |
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety | 2015 |
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Topics: Adolescent; Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Cell Proliferation; Cells, Cultured; Child; Child, Preschool; Combined Modality Therapy; Decitabine; Dendritic Cells; Feasibility Studies; Female; Humans; Male; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neuroblastoma; Peptide Fragments; Recurrence; Sarcoma; T-Lymphocytes; Treatment Outcome | 2015 |
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Topics: Adult; Aged; Azacitidine; Drug Administration Schedule; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2016 |
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Survival Rate | 2017 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate | 2017 |
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Topics: Adult; Aged; Azacitidine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation, Homologous | 2010 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chimerism; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Recurrence; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Transplantation; Combined Modality Therapy; Female; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2013 |
Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Risk Factors; Survival Rate | 2006 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Recurrence | 1993 |
Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Female; Humans; Leukemia; Male; Middle Aged; Pilot Projects; Recurrence | 1996 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Time Factors | 1997 |
Studies of decitabine with allogeneic progenitor cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas Infections; Recurrence; Time Factors; Transplantation, Homologous | 1997 |
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2001 |
83 other study(ies) available for azacitidine and Recrudescence
| Article | Year |
|---|---|
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study
Topics: Azacitidine; Belgium; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2022 |
Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Male; Recurrence; RUNX1 Translocation Partner 1 Protein; Transplantation, Homologous | 2022 |
Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Sulfonamides | 2022 |
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Retrospective Studies; Transplantation Conditioning | 2022 |
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
Erythema nodosum after azacitidine in a patient with acute myeloid leukemia.
Topics: Adult; Azacitidine; Erythema Nodosum; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Sorafenib | 2023 |
Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
Topics: Azacitidine; Humans; Janus Kinase 2; Leukemia; Lymphocyte Activation; Mutation; Myeloproliferative Disorders; Neoplasms; Recurrence | 2022 |
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Topics: Adult; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies | 2023 |
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Topics: Antigens, CD34; Azacitidine; Chimerism; Chronic Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Recurrence | 2023 |
[Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia].
Topics: Azacitidine; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Juvenile; Male; Prospective Studies; Recurrence | 2023 |
Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Transplantation, Homologous | 2023 |
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Recurrence; RNA-Binding Proteins; Transcription Factors | 2023 |
Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Danazol; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Young Adult | 2023 |
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Analysis; Treatment Outcome | 2020 |
Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2020 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
Hypomethylating agents and venetoclax in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome | 2021 |
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation, Homologous | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.
Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Infant; Male; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2017 |
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bacterial Toxins; Bone Marrow; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Exotoxins; Humans; Leukemia; Mice; Neoplasms, Experimental; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2018 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic
Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous | 2019 |
Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Fatal Outcome; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Salvage Therapy; Transplantation, Homologous; Up-Regulation; Valproic Acid | 2013 |
Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Count; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2013 |
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2013 |
[Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Cord Blood Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Recurrence; Treatment Outcome | 2013 |
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine | 2014 |
DLI after haploidentical BMT with post-transplant CY.
Topics: Adolescent; Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Leukemia; Living Donors; Lymphocyte Transfusion; Middle Aged; Recurrence; Survival Rate; Time Factors | 2015 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Neoplasms; Cell Line, Tumor; Chordoma; Decitabine; DNA Methylation; Female; Gene Expression; Genome; Humans; Male; Middle Aged; Recurrence | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bortezomib; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Recurrence | 2015 |
Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Azacitidine; Disease-Free Survival; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2015 |
Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
Topics: Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; MicroRNAs; Multiple Myeloma; Phenotype; Promoter Regions, Genetic; Recurrence; Treatment Outcome | 2015 |
[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Azacitidine; Decitabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Topics: Adult; Aged; Allografts; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous | 2016 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Topics: Adult; Aged; Azacitidine; Case-Control Studies; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondrial Proton-Translocating ATPases; Promoter Regions, Genetic; Recurrence; Remission Induction; Young Adult | 2016 |
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2016 |
Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Decitabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome | 2016 |
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Predictive Value of Tests; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Comorbidity; Decitabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Living Donors; Middle Aged; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2008 |
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous | 2009 |
Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Proto-Oncogene Proteins c-abl; Recurrence | 2010 |
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Topics: Adult; Aged; Azacitidine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous | 2010 |
Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
Topics: Adult; Azacitidine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2010 |
Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy | 2010 |
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Male; Myelodysplastic Syndromes; Neoadjuvant Therapy; Recurrence; Retrospective Studies; Survival Rate; Transplantation Chimera | 2010 |
Azacitidine: a new medication associated with Sweet syndrome.
Topics: Aged; Azacitidine; Drug Eruptions; Enzyme Inhibitors; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Myelodysplastic Syndromes; Recurrence; Sweet Syndrome | 2011 |
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Treatment Outcome | 2011 |
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Epitopes; Feasibility Studies; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Molecular Targeted Therapy; Neoplasm Proteins; Recurrence; T-Lymphocytes; Up-Regulation | 2011 |
Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.
Topics: Animals; Astrocytes; Azacitidine; Blotting, Western; Brain; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Neoplasm Grading; Neurons; Oligodendroglia; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Recurrence; RNA, Messenger | 2011 |
Epigenetic inactivation of the MIR34B/C in multiple myeloma.
Topics: Azacitidine; Base Sequence; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Multiple Myeloma; Primary Cell Culture; Recurrence; Tumor Cells, Cultured | 2011 |
Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence.
Topics: Azacitidine; Cell Line, Tumor; Disease-Free Survival; DNA Methylation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Male; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence | 2012 |
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Topics: Antigens, CD; Azacitidine; Case-Control Studies; Cell Lineage; Chromosome Aberrations; Chromosomes, Human, Pair 7; DNA Methylation; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Hematopoietic Stem Cells; Humans; Karyotyping; Myelodysplastic Syndromes; Primary Cell Culture; Recurrence; STAT3 Transcription Factor | 2012 |
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Cohort Studies; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult | 2013 |
Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma.
Topics: Azacitidine; Cancer Vaccines; Child; Decitabine; Dendritic Cells; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Recurrence; Remission Induction | 2013 |
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mouth Neoplasms; Recurrence; Skin Neoplasms | 2013 |
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.
Topics: Aged; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; T-Lymphocytes, Regulatory; Transplantation, Homologous; Treatment Outcome | 2013 |
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies | 2013 |
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acid Anhydride Hydrolases; Acute Disease; Azacitidine; Bone Marrow; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Recurrence; RNA, Messenger; Tumor Suppressor Proteins | 2005 |
Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Methylation; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Survival Rate; Tretinoin; Tumor Cells, Cultured | 2006 |
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors | 2006 |
Azacitidine pharmacokinetics in an adolescent patient with renal compromise.
Topics: Acute Disease; Adolescent; Azacitidine; Chimerism; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Recurrence; Renal Insufficiency; Treatment Outcome | 2007 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Middle Aged; Prognosis; Recurrence | 1983 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Decitabine; Drug Resistance; Female; Humans; Leukemia; Male; Middle Aged; Recurrence | 1991 |